1a.Objectives (from AD-416):
Generate research data through collaborative effort: obtain limited use permit for experimental Bm86-based veterinary biological product from APHIS Center for Veterinary Biologics, and perform Cattle Fever Tick Eradication Program.
1b.Approach (from AD-416):
Studies will be planned and executed according to APHIS Center for Veterinary Biologics General Licensing Considerations for Efficacy Studies. Cooperator will prepare and provide the ARS two experimental vaccine formulations containing the antigen Bm86 for efficacy testing. Each of the two experimental Bm86-based vaccines will be tested for efficacy against Rhipicephalus annulatus and R. microplus by the Cattle Fever Tick Research Laboratory. Studies will be reported according to APHIS Center for Veterinary Biologics General Licensing Considerations for Efficacy Studies.
Studies were completed using two BM86-based vaccine formulations on both R. annulatus and R. micorplus. Very high efficacy was observed in both formulations against R. annulatus (>99%) and good efficacy was observed for R. microplus (54% and 65% for formulation 1 and 2, respectively). Randomly selected animals were necropsied,and all data were sent to CVB for consideration. Plans are now underway for a field safety experiment, followed by vaccination of all cattle (>10,000 head) in the Cattle Fever Tick Eradication Zone within 6 months. This represents the first non-chemical control technique used in the 107-year-old Cattle Fever Tick Eradication Program and represents a great step to create an integrated and sustainable approach to maintain the eradication of cattle fever tick from the USA.